The University of North Carolina at Chapel Hill (UNC-CH) has enrolled approximately 65 treatment cases (including 10-15 minority accruals/year) plus 50-120 companion studies annually for the past four years. Our affiliate network is responsible for another 78-99 treatment accruals/year while maintaining excellent data quality control. UNC has broad leadership participation in the Group in Breast, Cancer Prevention and Control, GI, Lymphoma, Molecular Pathology, Pharmaceutics and Experimental Therapeutics, Radiation Oncology and Transplant, and is the research base for a UNC based Minority Initiative Program and a VCU based Minority CCOP. During the past five years, UNC has had four committee chairs, eight committee vice-chairs, seven administrative committee members, 14 modality committee members or modality committee liaisons, 14 scientific committee members or scientific committee liaisons, two Executive Committee members, two members of the Board of Directors, and seven protocol principal investigators. Members from UNC and its affiliates have chaired more than 35 studies and contributed to over 130 manuscripts and abstracts. Faculty at UNC-CH have expanded our commitment and Group leadership in the Breast, Surgery, GU, GI, Lymphoma, Solid Tumor Correlative Sciences, Thoracic, and PET committees (L. Carey, C. Dees, L. Dressler, R. Goldberg, H McLeod, B. O'Neil, R. Pruthi, C. Sartor, T. Shea, and M. Socinski). The addition of Drs. Goldberg (Chair, GI Committee), Howard McLeod (Vice Chair, PET Committee), and Charles Perou (Vice Chair, Breast Committee), have significantly enhanced our role in the Group. We therefore believe that this renewal application reflects the growing and crucial contribution that UNC-CH investigators provide to the Group in leadership, science, and service as well as our continued efforts to increase accrual both at UNC-CH and through affiliate members while maintaining rigorous control of quality data submission.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Attar, Eyal C; Johnson, Jeffrey L; Amrein, Philip C et al. (2013) Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 31:923-9
Walker, Alison; Mrozek, Krzysztof; Kohlschmidt, Jessica et al. (2013) New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Genes Chromosomes Cancer 52:385-401
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43

Showing the most recent 10 out of 112 publications